The overall goal of our laboratory is the development of new methodology and strategy-level insights of value to organic synthesis. These advances are then applied to the assembly of complex, biologically active synthetic targets. We strive to bring these advances to bear in understanding structure-activity relationships (SAR) of complex small molecules and carbohydrate-based constructs. Our research program for CA28824 can be divide into three general categories. In the first, we are focused on the total synthesis of structurally interesting natural products of biological value. Some of the targets that we have selected for the upcoming grant period include: spiculoic acid, lyconadin, and pluraflavin. In addition, we have an ongoing program devoted to the preparation of fully synthetic, carbohydrate-based antitumor vaccines. In the upcoming grant period, we will be targeting a hexavalent vaccine construct as well as a "cluster of clusters" vaccine, which we hope will have great value in treating prostate cancer. We also hope to complete the synthesis of a clustered fucosyl-GM1 vaccine construct, targeting small cell lung carcinoma. Finally, a third subprogram is focused on the development of methods to allow for the preparation of fully synthetic glycoproteins. A long-term goal of this program is the preparation of homogeneous erythropoietin.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA028824-33
Application #
8010653
Study Section
Special Emphasis Panel (NSS)
Program Officer
Lees, Robert G
Project Start
1980-03-01
Project End
2012-04-30
Budget Start
2011-01-01
Budget End
2012-04-30
Support Year
33
Fiscal Year
2011
Total Cost
$771,834
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Wilson, Rebecca M; Danishefsky, Samuel J (2013) A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic. J Am Chem Soc 135:14462-72
Brailsford, John A; Danishefsky, Samuel J (2012) Probing the stability of nonglycosylated wild-type erythropoietin protein via reiterative alanine ligations. Proc Natl Acad Sci U S A 109:7196-201
Townsend, Steven D; Tan, Zhongping; Dong, Suwei et al. (2012) Advances in proline ligation. J Am Chem Soc 134:3912-6
Wilson, Rebecca M; Stockdill, Jennifer L; Wu, Xiangyang et al. (2012) A fascinating journey into history: exploration of the world of isonitriles en route to complex amides. Angew Chem Int Ed Engl 51:2834-48
Wang, Ping; Dong, Suwei; Brailsford, John A et al. (2012) At last: erythropoietin as a single glycoform. Angew Chem Int Ed Engl 51:11576-84
Wu, Xiangyang; Stockdill, Jennifer L; Park, Peter K et al. (2012) Expanding the limits of isonitrile-mediated amidations: on the remarkable stereosubtleties of macrolactam formation from synthetic seco-cyclosporins. J Am Chem Soc 134:2378-84
Wu, Xiangyang; Park, Peter K; Danishefsky, Samuel J (2011) On the synthesis of conformationally modified peptides through isonitrile chemistry: implications for dealing with polypeptide aggregation. J Am Chem Soc 133:7700-3
Shang, Shiying; Tan, Zhongping; Danishefsky, Samuel J (2011) Application of the logic of cysteine-free native chemical ligation to the synthesis of Human Parathyroid Hormone (hPTH). Proc Natl Acad Sci U S A 108:5986-9
Tan, Zhongping; Shang, Shiying; Danishefsky, Samuel J (2011) Rational development of a strategy for modifying the aggregatibility of proteins. Proc Natl Acad Sci U S A 108:4297-302
Shang, Shiying; Tan, Zhongping; Dong, Suwei et al. (2011) An advance in proline ligation. J Am Chem Soc 133:10784-6

Showing the most recent 10 out of 101 publications